Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia

NCT05827549 is registered in ClinicalTrials.gov with Ho Joon Im as lead sponsor.

NCT NCT05827549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05827549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia
Lead sponsor
Ho Joon Im
Phase
Phase 2
Overall status
Recruiting
Start date
April 4, 2024
Completion date
December 31, 2032
Enrollment
90 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoid leukemia